



**Arix Bioscience plc**

**Result of Annual General Meeting 2022**

**LONDON, 7 June 2022:** Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.

Full details of the poll results are set out below and will also be available on the Company's [website](#).

No	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	TOTAL VOTES	% of ISC VOTED	VOTES WITHHELD
1	To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2021	63,669,622	99.99%	5,609	0.01%	63,675,231	49.29%	10,853
2	To approve the Directors' Remuneration Policy	63,589,770	99.90%	65,188	0.10%	63,654,958	49.28%	31,126
3	To approve the Directors' Remuneration Report	60,232,861	94.62%	3,422,747	5.38%	63,655,608	49.28%	30,476
4	To re-elect Peregrine Moncreiffe as a Director	60,068,424	94.35%	3,599,164	5.65%	63,667,588	49.29%	18,496
5	To re-elect Maureen O'Connell as a Director	59,600,160	93.61%	4,068,028	6.39%	63,668,188	49.29%	17,896
6	To re-elect Isaac Kohlberg as a Director	63,450,417	99.66%	217,771	0.34%	63,668,188	49.29%	17,896
7	To re-elect Robert Lyne as a Director	63,451,455	99.66%	216,733	0.34%	63,668,188	49.29%	17,896
8	To elect Sir Michael Bunbury as a Director	60,231,844	94.60%	3,436,344	5.40%	63,668,188	49.29%	17,896
9	To appoint BDO LLP as auditors of the Company	63,659,891	99.98%	12,947	0.02%	63,672,838	49.29%	13,246
10	To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration	63,667,766	99.99%	4,772	0.01%	63,672,538	49.29%	13,546
11	To authorise the Directors to allot shares	63,632,590	99.94%	40,130	0.06%	63,672,720	49.29%	13,364
12	Authority to disapply statutory pre-emption rights	58,648,467	92.11%	5,021,253	7.89%	63,669,720	49.29%	16,364
13	Additional authority to disapply statutory pre-emption rights	58,653,953	92.12%	5,015,767	7.88%	63,669,720	49.29%	16,364
14	To authorise the Company to purchase its own shares	63,648,630	99.96%	22,560	0.04%	63,671,190	49.29%	14,894
15	Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice	63,666,745	99.99%	8,786	0.01%	63,675,531	49.29%	10,553

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 12 May 2022, which is available on Arix investor relations [website](#).

[ENDS]

**Enquiries**

For more information on Arix, please contact:

**Arix Bioscience plc**

+44 (0)20 7290 1050

[ir@arixbioscience.com](mailto:ir@arixbioscience.com)

**Powerscourt Group**

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

[arix@powerscourt-group.com](mailto:arix@powerscourt-group.com)

**About Arix Bioscience plc**

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. [www.arixbioscience.com](http://www.arixbioscience.com)